As Cerulean continues to grow and advance our technologies and programs, we are committed to clear and consistent communication to our external audiences. Here we feature current and historic information concerning our technology, our pipeline and our corporate goals and achievements. Please check in often for the most recent press releases and news coverage.

In The News

Boston Globe
03.13.11 – Boston Globe
Everything you need to know about biotech — on five floors in Cambridge


Xconomy Boston
01.25.11 – Xconomy Boston
Massachusetts Startups Snag $175M in November, Money Raised for Drugs


Xconomy Boston


– Xconomy Boston

Massachusetts Startups Snag $175M in November, Money Raised for Drugs


BioCentury Part II
01.06.11 – PharmaVoice
Raising Capital in a Tight Market


BioCentury Part II
11.22.10 – BioCentury PartII
Cerulean raised $16 million in a first close of a planned $24 million series C round


BioCentury Part II
11.22.10 – BioCentury PartII
Appointed: Steve Hall, venture partner at Lilly Ventures


Dow Jones VentureWire Lifescience
11.16.10 – Dow Jones Venture Wire Lifescience
Cerulean Raises $24M Series C, Heads Into Phase II Lung Cancer Trials


BioWorld Today
11.16.10 – BioWorld Today
Cerulean Pushing Nano-based Pipeline via $24M Series C


11.15.10 – The IN VIVO Blog
Financings of the Fortnight Stops Complaining and Learns to Live The Man


Boston Business Journal
11.15.10 – Boston Business Journal
Cerulean Pharma pins down $24M in Series C funding


BioCentury Extra
11.15.10 – BioCentury Extra
Cerulean raises $16M


11.15.10 – Xconomy Boston
Cerulean Grabs $24M for Nano Drugs


10.26.10 – Pharmaceutical Approvals Monthly
Nanopharma Cerulean Advances Cancer Particle, Looks Ahead To siRNA


Science Magazine
10.15.10 – Science Magazine
Nanoparticle Trojan Horses Gallop From the Lab Into the Clinic


10.05.10 – CNN Health
Cancer ‘iron man’ puts hope in drug trials


09.07.10 – Xconomy | Boston Cerulean Pharma Makes Progress in Attacking the Big C with Tiny Drugs


08.27.10 – Boston Globe
Cerulean encouraged by results of early clinical test for its lead drug candidate, CRLX101


03.29.10 – Boston Globe
What’s up with nanotech? Ultrasmall wonders are opening big new frontiers, despite fading of the initial excitement


03.24.10 – Scientific American
Thinking Outside of the Toy Box: 4 Children’s Gizmos That Inspired Scientific Breakthroughs


03.29.10 :: Forbes Video Network

Fighting Cancer With Nanoparticals; Interview with Oliver Fetzer, President & CEO Cerulean Pharma Inc.

View Video

Recent Press Releases

04.04.11 Cerulean Pharma Inc. Presents Phase 2a Clinical Data at American Association for Cancer Research (AACR) 102nd Annual Meeting 2011

12.09.10 Cerulean Pharma Inc. Senior Executive to Present at the National Nanotechnology Innovation Summit

11.18.10 Cerulean Pharma Inc. Presents Clinical and Pre-Clinical Nanopharmaceutical Data at EORTC-NCI-AACR

11.15.10 Cerulean Pharma Inc. Closes $24 Million in Series C Financing

11.11.10 Cerulean Pharma Inc. to Present at BIO-Europe and EORTC-NCI-AACR

09.16.10 Cerulean Pharma Inc. CEO to Present at BioPharm AmericaTM 2010

08.25.10 Cerulean Pharma Inc. Presents Data on Nanopharmaceutical Development Candidates and Platform Technologies at American Chemical Society (ACS)

08.19.10 Cerulean Pharma Inc. to Convene Nanomedicine Pioneers at 2010 American Chemical Society (ACS)

03.10.10: Cerulean Pharma Inc. Appoints Two Senior Executives to Management Team

07.28.09 Cerulean Pharma Inc. Closes $10 Million Series B-1 Financing

06.23.09 Cerulean Pharma Inc. Announces License Agreement with Calando Pharmaceuticals, Inc.

04.08.09 Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and Chief Executive Officer

01.23.09 Sandra Glucksmann Named 2009 Mass High Tech Woman to Watch

10.24.08 Tempo Pharmaceuticals, Inc. Announces Name Change to Cerulean Pharma Inc.

01.03.08 Tempo Pharmaceuticals Closes $8 Million in Series B Funding

05.23.07 Tempo Pharmaceuticals Closes $12.1 Million in Series A Funding